Chordia Therapeutics Inc.
26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-0012, Japan
ir@chordiatherapeutics.com

This press release is an English translation of a Japanese-language press release. The official language of this press release is Japanese, and the Japanese version takes precedence over the English version in terms of content and interpretation.

<Press Release>
27th January 2026

Company: Chordia Therapeutics Inc
Representative: Chief Executive Officer Hiroshi Miyake
(Security Code: 190A TSE Growth Market)
Contact: IR Manager Ami Kira

Chordia Therapeutics Publishes Phase 1 Results of CLK Inhibitor Rogocekib for R/R AML/HR-MDS in *Blood Advances* (Follow-up announcement)

Chordia Therapeutics Inc (Head Office: Fujisawa City, Kanagawa Prefecture; CEO: Hiroshi Miyake, "Chordia") hereby announces that the final, fully formatted version. including completed figures and tables, of the peer-reviewed article summarizing the final results of the Phase 1 Trial of CLK inhibitor, rogocekib (CTX-712), for patients with hematologic malignancies conducted in Japan, has been published in *Blood Advances* on January 13, 2026. This follows the article's initial online publication on October 14, 2025. In addition, we are pleased to announce that *Blood Advances* has simultaneously published an expert commentary article authored by independent third-party oncology experts evaluating the significance of the results of our study.

Publication Details

Phase I Study of Rogocekib in Patients with Relapsed or Refractory Hematologic Malignancies

Yokoyama H, Fukuhara N, Ando K, et al. Phase I study of rogocekib in patients with relapsed or refractory hematologic malignancies. *Blood Adv*. 2026;10(1):262-272.

URL: https://ashpublications.org/bloodadvances/article/10/1/262/547633/Phase-1-study-of-rogocekib-in-patients-with

Expert Commentary

An expert commentary article authored by Dr. Evan C. Chen from the Leukemia Division of the Dana-Farber Cancer Institute in Boston, USA, and Dr. Maximilian Stahl from the Section of Medical Oncology and Hematology of the Yale Comprehensive Cancer Center in New Haven, USA, has also been published. The commentary provides a positive assessment of the antitumor activity and the manageable and tolerable safety profile demonstrated by rogocekib in patients with

relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).

The authors also note continued interest in the ongoing Phase 1/2 study in the United States (NCT05732103) and in the future clinical development of the drug.

Key Highlights from the Commentary

- With an overall manageable and tolerable safety profile and an objective response rate of 42.9%, rogocekib is considered a promising agent with a novel mechanism of action.
- Changes in splicing were observed in target genes, suggesting consistency between the pharmacodynamic effect and clinical efficacy.
- A higher response rate of 75% was observed in patients with splicing factor mutations (SRSF2, U2AF1), indicating the potential for patient stratification.
- Looking ahead, further progress is anticipated in clinical development, including U.S. clinical studies using a new formulation (tablet formulation instead of capsules in the U.S. trial) and exploration of synergistic effects through combination therapy with the BCL-2 inhibitor venetoclax.

It was disclosed that Dr. Chen serves as the principal investigator for the Phase 1 clinical study (NCT06484062) of cirtuvivint, a product under development by Biosplice and considered a competitive agent to rogocekib.

Chordia recognizes that the publication of an independent expert commentary alongside our article signifies that the editorial board of the journal highly values the scientific content of the paper and considers the findings to be of particular importance to its readership.

Chordia is encouraged by the fact that rogocekib is attracting scientific interest and positive expectations as an investigational drug with a novel mechanism of action. Chordia remains committed to advancing its development as rapidly as possible to deliver a new treatment option to a greater number of patients with AML and MDS.

Commentary Publication Details

More than CLK bait? Rogocekib for MDS and AML

Chen EC, Stahl M. More than CLK bait? Rogocekib for MDS and AML. Blood Advances. 2026 Jan 13;10(1):260-1.

URL: https://ashpublications.org/bloodadvances/article/10/1/260/565923/More-than-CLK-bait-Rogocekib-for-MDS-and-AML

About Chordia Therapeutics

Chordia's lead asset, rogocekib (CLK inhibitor CTX-712), is under Phase 1/2 clinical study in the US. Rogocekib potentially targets the vulnerability of cancer and is

expected to deliver benefits to patients of various types of cancer. In addition to rogocekib, Chordia is engaged in the research and development of several assets, including CTX-177, a MALT1 inhibitor, CTX-439, a CDK12 inhibitor, and GCN2 inhibitors. For more information, please visit our website https://www.chordiatherapeutics.com/en/.